Therefore, future research should focus on elucidating the molecular interplay between LTβR, NF-κB signaling, and p53 in various cancer types and exploring combination therapies to exploit LTβR–p53 dynamics for improved cancer treatment outcomes. This evidence concerns the gene NFKB1 and cancer.